Skip to main content
OpenTrials
Completed

NCT Number: NCT02885363

Prognosis of Isolated Left Ventricular Non-compaction in Adults

The main objective of this study is to clarify prospectively prognosis of patients newly diagnosed as carriers of a LVNC (incident cases) (i.e. without the occurrence of a survival of the following events: death, heart transplantation or hospitalization for cardiovascular complications). In a second time, prognosis factors will be identify in these patients with LVNC.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Assistance Publique Hôpitaux de Marseille, Hôpital de la Timone

Marseille, 13005, France

About this study

Isolated Left Ventricular Non Compaction (LVNC) is a rare cause of cardiomyopathy supposed to result from the cessation of normal embryogenesis infarction, and characterized by persistent ventricular trabeculations prominent.

This is frequently a familial disease, but for which genetic characterization is still incomplete, and then requires the identification of new genes is desirable.

The prognosis of LVNC is uncertain, with a mortality rate reported in the literature ranging from 2 to 38%. Some series conclude that LVNC is a very severe heart disease, responsible for a high mortality, other that LVNC is frequently associated with a favorable prognosis. These series are however limited by the short duration of follow-up and the small number of patients included.

Between 2004 and 2006, a French registry LVNC, included 105 cases. It was found out that the LVNC was associated with a high rate of complications such as outbreaks of severe heart failure, need for heart transplantation, severe rhythm disorders, and embolic events. The prognosis of LVNC in France appears as pejorative:

  • - there is no evidence that prognosis is different from other forms of cardiomyopathies.
  • - the results of this register can be skewed by the inclusion of incident and prevalent cases (statistical survival bias).

Thus, a longer-term monitoring and the identification of relevant prognostic markers are imperative to better understand this rare disease and to improve the therapeutic management.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female aged over 18 years
  • Presenting with Left Ventricular Non Compaction (LVNC, Group 1) or Idiopathic Dilated Cardiomyopathy (DCM, Group 2)
  • At distance of an acute heart failure thrust (> 1 month)
  • Newly diagnosed (less than 6 months)
  • Diagnosis confirmed by echocardiography associated or not with a Magnetic Resonance Imaging (MRI) confirmed after central review
  • Having signed informed consent form

Exclusion criteria

  • Age <18 years
  • Patients who were diagnosed more than 6 months ago (prevalent cases)
  • Presence of an associated cardiac disease, including valvular, ischemic, or congenital disease
  • Refusal to sign the informed consent form

Treatment and study plan

Clinical examination

Other

blood sample

Other

Echocardiography

Procedure

Primary outcomes

  1. Occurrence of death of cardiac origin

    Time frame: Up to 2 years

  2. Occurrence of a cardiac transplantation

    Time frame: Up to 2 years

  3. Occurrence of hospitalization due to cardiac event

    Time frame: Up to 2 years

Sponsors and collaborators

Lead sponsor

Assistance Publique Hopitaux De Marseille

Other

Registry information

Acronym: NCVG

Important dates

Study start
2011
Primary completion
2015
Study completion
2023
First posted
Aug 31, 2016
Registry last updated
Apr 14, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.